Immuneering presents design and methodology of ongoing Phase 3 MAPKeeper 301 trial at ESMO Congress 2026
IMRX•Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeeper 301 trial at ESMO Congress 2026.
1. Trial presentation
Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeeper 301 trial at ESMO Congress 2026.
